valsartan 80 mg comprimate filmate
sandoz pharmaceuticals d.d. - lisinoprilum - comprimate filmate - 80 mg
viasart 320 mg comprimate filmate
world medicine ltd - lisinoprilum - comprimate filmate - 320 mg
viasart 160 mg comprimate filmate
world medicine ltd - lisinoprilum - comprimate filmate - 160 mg
viasart 80 mg comprimate filmate
world medicine ltd - lisinoprilum - comprimate filmate - 80 mg
valsartan stadafarma 160 mg comprimate filmate
laboratorio stada, s.l. - lisinoprilum - comprimate filmate - 160 mg
valsartan stadafarma 80 mg comprimate filmate
laboratorio stada, s.l. - lisinoprilum - comprimate filmate - 80 mg
melatonin neurim
rad neurim pharmaceuticals eec sarl - melatonină - tulburări de inițiere și întreținere a somnului - psiholeptice - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.
bortega 3,5 mg
pharmidea sia - letonia - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice
dolac solutie injectabila 30 mg/ml
cadila pharmaceuticals ltd - ketorolacum - solutie injectabila - 30 mg/ml